blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3263566

EP3263566 - BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AS ALLOSTERIC MODULATORS OF THE METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLU5 OR MGLUR5) FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) DISORDERS [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  30.11.2018
Database last updated on 03.09.2024
FormerRequest for examination was made
Status updated on  06.07.2018
FormerThe application has been published
Status updated on  01.12.2017
Most recent event   Tooltip30.11.2018Application deemed to be withdrawnpublished on 02.01.2019  [2019/01]
Applicant(s)For all designated states
H. Lundbeck A/S
Ottiliavej 9
2500 Valby / DK
[2018/01]
Inventor(s)01 / LI, Guiying
76 Rutgers Place, Apt. No. 1
River Edge, NJ 07661 / US
02 / ZHOU, Hao
325 Edstan Way
Paramus, NJ 07652 / US
03 / WEISS, Jesse
169 South Park Drive
Woodbridge, NJ 07095 / US
04 / DOLLER, Dario
15 Quarterhorse Crossing
Sparta, NJ 07871 / US
05 / BURNS, James, Ford
11 Madison Street
Glen Ridge, NJ 07028 / US
 [2018/01]
Application number, filing date17178046.322.12.2011
[2018/01]
Priority number, dateUS201061426379P22.12.2010         Original published format: US 201061426379 P
[2018/01]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3263566
Date:03.01.2018
Language:EN
[2018/01]
Search report(s)(Supplementary) European search report - dispatched on:EP10.10.2017
ClassificationIPC:C07D401/12
[2018/01]
CPC:
C07D417/12 (EP,CN,US); C07D401/12 (EP,CN,KR,US); C07D213/81 (EP,CN,US);
A01N43/40 (KR); A61P25/00 (EP); A61P25/04 (EP);
A61P25/06 (EP); A61P25/18 (EP); A61P25/22 (EP);
A61P25/24 (EP); A61P25/28 (EP); A61P29/00 (EP);
A61P43/00 (EP); C07D213/75 (EP,US); C07D213/82 (EP,US);
C07D239/28 (EP,US); C07D239/42 (EP,US); C07D241/20 (EP,US);
C07D241/24 (EP,CN,US); C07D277/56 (EP,US); C07D403/12 (EP,CN,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/32]
Former [2018/01]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
Extension statesBA03.07.2018
ME03.07.2018
TitleGerman:BICYCLO[3.2.1]OCTYLAMID-DERIVATE ALS ALLOSTERISCHE MODULATOREN DES METABOTROPISCHEN GLUTAMAT-REZEPTORS 5 (MGLU5 ODER MGLUR5) ZUR BEHANDLUNG VON STÖRUNGEN DES ZENTRALEN NERVENSYSTEMS (ZNS)[2018/01]
English:BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AS ALLOSTERIC MODULATORS OF THE METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLU5 OR MGLUR5) FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) DISORDERS[2018/01]
French:DÉRIVÉS D'AMIDE BICYCLO[3.2.1]OCTYL EN TANT QUE MODULATEURS ALLOSTERIQUES DU RÉCEPTEUR 5 MÉTABOTROPIQUE DU GLUTAMATE (MGLU5 OU GLUR5) POUR LE TRAITEMENT DES TROUBLES DU SYSTÈME NERVEUX CENTRAL (SNC)[2018/01]
Examination procedure27.06.2017Date on which the examining division has become responsible
03.07.2018Examination requested  [2018/32]
04.07.2018Application deemed to be withdrawn, date of legal effect  [2019/01]
16.08.2018Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time  [2019/01]
Parent application(s)   TooltipEP11852103.8  / EP2654422
Fees paidRenewal fee
27.10.2017Renewal fee patent year 03
27.10.2017Renewal fee patent year 04
27.10.2017Renewal fee patent year 05
27.10.2017Renewal fee patent year 06
02.01.2018Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]WO2010011570  (LUNDBECK & CO AS H [DK], et al) [A] 1-15 * page 1, line 7 - line 9 ** claims 1, 18, 19, 21, 22 *
by applicant   - G. JAESCHKE et al., "mGlu5 receptor antagonists and their therapeutic potential", Expert Opin. Ther. Patents, (20080000), vol. 18, no. 2, doi:doi:10.1517/13543776.18.2.123, pages 123 - 142, XP002522663

DOI:   http://dx.doi.org/10.1517/13543776.18.2.123
    - P. BACH et al., "Metabotropic glutamate receptor 5 modulators and their potential therapeutic applications", Expert Opin. Ther. Patents, (20070000), vol. 17, no. 4, doi:doi:10.1517/13543776.17.4.371, pages 371 - 381, XP002549979

DOI:   http://dx.doi.org/10.1517/13543776.17.4.371
    - S.M. BERGE et al., J. Pharm. Sci., (19770000), vol. 66, no. 1, page 2
    - G.S. PAULEKUHN et al., J. Med. Chem., (20070000), vol. 50, no. 26, pages 6665 - 6672
    - MAY, L.T., Annu. Rev. Pharmacol. Toxicol., (20070000), vol. 47, pages 1 - 51
    - J. A. O'BRIEN et al., Mol Pharmacol., (20030000), vol. 64, pages 731 - 740
    - Y. CHENG; W.H. PRUSOFF, Biochem. Pharmacol., (19730000), vol. 22, pages 3099 - 3108
    - K. NJUNG'E, K.; S.L. HANDLEY, Pharmacology, Biochemistry and Behavior, (19910000), vol. 38, pages 63 - 67
    - N.A. MOORE et al., Behavioural Pharmacology, (19940000), vol. 5, pages 196 - 202
    - VOGEL et al., Psychopharmacologia, (19710000), vol. 21, pages 1 - 7
    - WALKER; DAVIS, Biol. Psychiatry, (19970000), vol. 42, pages 461 - 471
    - S.E. FILE; P. SETH, European Journal of Pharmacology, (20030000), vol. 463, pages 35 - 53
    - S.M. KORTE; S.F. DE BOER, European Journal of Pharmacology, (20030000), vol. 463, pages 163 - 175
    - J.F. CRYAN et al., Neuroscience and Biobehavioral Reviews, (20050000), vol. 29, pages 547 - 569
    - D.H. OVERSTREET; G. GRIEBEL, Pharmacol Biochem Behav., (20050000), vol. 82, no. 1, pages 223 - 227
    - E. H. LEE et al., Chin. J. Physiol., (19920000), vol. 35, no. 4, pages 317 - 36
    - W. SCHULTZ, Prog. Neurobiol., (19820000), vol. 18, no. 2-3, pages 121 - 66
    - L. E. ANNETT et al., Exp. Neurol., (19940000), vol. 125, no. 2, pages 228 - 46
    - N. BREYSSE et al., J. Neurosci., (20020000), vol. 22, no. 13, pages 5669 - 5678
    - D. RYLANDER et al., J. Pharmacol. Exp. Ther., (20090000), vol. 330, no. 1, pages 227 - 235
    - L. CHEN et al., "Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist in 6-hydroxydopamine partially lesioned rats reverses abnormal firing of dopaminergic neurons", Brain Res., (20090000), vol. 1286, pages 192 - 200, XP026422857
    - Q.J. YAN et al., Neuropharmacol., (20050000), vol. 49, pages 1053 - 1066
    - G. DOLEN et al., Neuron, (20070000), vol. 56, pages 955 - 962
    - R. DEPOORTERE et al., Neuropsychopharmacology, (20030000), vol. 28, no. 11, pages 1889 - 902
    - W. J. FREED et al., Neuropharmacology, (19840000), vol. 23, no. 2A, pages 175 - 81
    - F. SAMS-DODD, Neuropsychopharmacology, (19980000), vol. 19, no. 1, pages 18 - 25
    - Y. K. FUNG et al., Pharmacol. Biochem. Behav., (19860000), vol. 24, no. 1, pages 139 - 41
    - Y. K. FUNG et al., Steroids, (19870000), vol. 49, no. 4-5, pages 287 - 94
    - T. J. GOULD et al., Behav. Pharmacol., (20020000), vol. 13, no. 4, pages 287 - 94
    - A. O. HAMM et al., Brain, (20030000), vol. 126, pages 267 - 75
    - J. P. AGGLETON et al., Behav. Brain Res., (19960000), vol. 19, no. 2, pages 133 - 46
    - MORRIS, Learn. Motiv., (19810000), vol. 12, pages 239 - 260
    - B. BONTEMPI et al., Eur. J. Neurosci., (19960000), vol. 8, no. 11, pages 2348 - 60
    - M. DAY; M. GOOD, Neurobiol. Learn. Mem., (20050000), vol. 83, no. 1, pages 13 - 21
    - J. L. MUIR et al., Psychopharmacology (Berl), (19950000), vol. 118, no. 1, pages 82 - 92
    - ROBBINS et al., Ann. N. Y. Acad. Sci., (19980000), vol. 846, pages 222 - 37
    - KIM; CHUNG, Pain, (19920000), vol. 50, pages 355 - 363
    - WHEELER-ACETO et al., Psychopharmacology, (19910000), vol. 104, pages 35 - 44
    - H. Y. LIU et al., J. Neurosci. Res., (20020000), vol. 70, no. 2, pages 238 - 48
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.